Genomic Evolution of Breast Cancer: How Acquired Gene Fusions Drive Metastatic Progression and Treatment Resistance

Highlights

The AURORA program (BIG 14-01) has identified a significantly higher burden of gene fusions in metastatic breast cancer lesions compared to paired primary tumors, highlighting the role of genomic rearrangements in disease progression. Acquired gene fusions—those present in metastasis but absent in the primary tumor—are linked to genomic instability and are particularly prevalent in patients who develop recurrent disease rather than those with de novo metastasis. Fusions involving the ESR1 gene are associated with aggressive disease phenotypes, shorter treatment response durations, and overall poorer clinical outcomes in ER-positive/HER2-negative breast cancer. The study highlights the colocalization of gene fusions within subtype-specific copy-number gains and topologically associating domains (TADs), providing new insights into the mechanical drivers of breast cancer evolution.

Background: The Uncharted Role of Gene Fusions in Breast Cancer

Gene fusions, resulting from chromosomal translocations, deletions, or inversions, have long been recognized as primary drivers in hematologic malignancies and certain soft tissue sarcomas. In solid tumors, such as lung cancer (ALK, ROS1) and prostate cancer (TMPRSS2-ERG), they serve as critical diagnostic markers and therapeutic targets. However, in breast cancer, the landscape of gene fusions—particularly their evolution from primary diagnosis to metastatic recurrence—has remained largely undefined. The complexity of the breast cancer genome, characterized by significant copy-number alterations and structural variations, suggests that gene fusions may play a more substantial role in therapy resistance and clonal expansion than previously appreciated. Understanding whether these fusions are early truncal events or acquired during the selective pressure of systemic therapy is vital for the next generation of precision medicine.

Study Design: The AURORA Program (BIG 14-01)

To address these questions, researchers utilized the robust multi-omics framework of the AURORA program. This international initiative focuses on the molecular characterization of metastatic breast cancer through the analysis of paired primary and metastatic samples. The study analyzed RNA sequencing data from a large cohort comprising 325 primary tumors and 350 metastatic lesions across 476 patients. The primary objective was to develop a high-confidence catalog of gene fusions and correlate these molecular events with clinical outcomes. A subset of 398 matched samples from 199 patients allowed for a direct comparison of the genomic landscape before and after metastatic progression. Investigators employed sophisticated bioinformatic pipelines to filter out technical noise and identify fusions with true oncogenic potential.

Key Findings: Fusion Burden and Genomic Instability

The research revealed several critical insights into the genomic architecture of advanced breast cancer.

Increased Fusion Burden in Metastasis

One of the most striking findings was the quantitative increase in gene fusions as the disease progresses. Metastatic tumors exhibited a higher burden of fusions compared to their corresponding primary tumors. This suggests that the process of metastasis, or the treatments administered in the interim, fosters an environment conducive to structural genomic rearrangements.

Acquired vs. De Novo Fusions

The study distinguished between truncal fusions (present in both primary and metastatic sites) and acquired fusions (detected only in the metastasis). Interestingly, patients with de novo metastatic disease (those presenting with stage IV disease at diagnosis) generally lacked the high burden of acquired fusions seen in patients who progressed from early-stage disease. This suggests that the evolutionary path of recurrent breast cancer involves a distinct accumulation of structural variations.

TADs and Subtype-Specific Patterns

The analysis found that gene fusions frequently occurred within the same topologically associating domains (TADs)—regions of the genome where DNA interacts more frequently with itself. These intra-TAD fusions were particularly common in HER2-positive tumors. In triple-negative breast cancer (TNBC), these fusions were frequently acquired during the metastatic transition. This colocalization with subtype-specific copy-number gains indicates that fusions are not random events but are tied to the underlying genomic instability of the tumor subtype.

Clinical Impact: Prognostic Significance and ESR1 Fusions

The clinical implications of these findings are profound, particularly for patients with estrogen receptor (ER)-positive/HER2-negative disease.

Prognostic Value

The presence of gene fusions, especially those that were acquired or involved genes within the same TAD, was independently associated with a poor prognosis. Patients harboring these rearrangements experienced faster disease progression and reduced overall survival, suggesting that fusion burden could serve as a biomarker for high-risk metastatic disease.

The Role of ESR1 Fusions

Perhaps the most clinically actionable finding involves the ESR1 gene. Acquired ESR1 fusions were identified as a key mechanism of resistance to endocrine therapy. Patients with these fusions exhibited a significantly more aggressive disease course. The study noted shorter response times to standard-of-care treatments and poorer clinical outcomes, highlighting the need for novel therapeutic strategies that can bypass or specifically target these ESR1 rearrangements.

Expert Commentary: Mechanistic Insights and Therapeutic Implications

The AURORA program’s findings shift the perspective on breast cancer from a disease driven primarily by point mutations and copy-number changes to one where structural rearrangements play a decisive role in late-stage evolution. The association between genomic instability scores and fusion burden reinforces the theory that as tumors lose DNA repair fidelity, the likelihood of forming oncogenic fusions increases. From a therapeutic standpoint, the AURORA gene fusion catalog provides a roadmap for drug development. While some fusions may be passenger events resulting from widespread genomic chaos, others—like those involving ESR1 or kinase domains—are clear drivers that could be neutralized with targeted inhibitors. The fact that many of these fusions are acquired underscores the importance of biopsying metastatic lesions rather than relying solely on primary tumor tissue for treatment planning.

Conclusion: Moving Toward Fusion-Directed Precision Oncology

The molecular and clinical analyses provided by the AURORA program (BIG 14-01) represent a significant step forward in our understanding of metastatic breast cancer. By identifying a higher burden of fusions in metastatic sites and linking specific rearrangements to poor clinical outcomes, this study highlights a previously underappreciated layer of tumor complexity. The AURORA gene fusion catalog serves as an essential resource for the scientific community. Future research must now focus on validating these fusions as therapeutic targets and integrating fusion detection into routine clinical practice. For clinicians, the message is clear: the metastatic genome is a dynamic entity, and the acquisition of gene fusions is a hallmark of the transition to an aggressive, treatment-resistant phenotype.

References

Biagioni C, Fimereli D, Irrthum A, et al. Molecular and clinical analyses of gene fusions identify therapeutic targets in paired primary and metastatic breast cancer from the AURORA program (BIG 14-01). Clin Cancer Res. 2025 Dec 22. doi: 10.1158/1078-0432.CCR-25-2707. PMID: 41427961.